UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of Report (date of earliest event reported): April 22, 2013
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
|
Florida
|
000-52491
|
26-2792552
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
60 Chastain Center Blvd., Suite 60
Kennesaw, GA
|
30144
(Zip Code)
|
|
|
(Address of principal executive offices)
|
(678) 384-6720
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
| Item 8.01 |
Other Events
|
On April 22, MiMedx Group, Inc., (“MiMedx” or the “Company”) issued a press release announcing that The NASDAQ Capital Market had approved the Company’s application to have its common stock listed for trading under the symbol “MDXG” on The NASDAQ Capital Market, effective as of the beginning of trading on April 25, 2013. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
(c) Exhibits
|
Exhibit No.
|
Description
|
|
|
MiMedx Group, Inc. Press Release, dated April 22, 2013
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MIMEDX GROUP, INC.
|
|||
|
Dated: April 22, 2013
|
By: |
/s/: Michael J. Senken
|
|
|
Michael J. Senken, Chief Financial Officer
|
|||
2
Exhibit 99.1
PRESS RELEASE Contact: Michael Senken
Phone: (678) 384-6720
MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
MiMedx Common Stock to begin trading on NASDAQ under the symbol “MDXG” on April 25, 2013
Kennesaw, Georgia, April 22, 2013 (PR Newswire) – MiMedx Group, Inc. (OTCBB: MDXG.OB), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol “MDXG.” Trading on NASDAQ is expected to commence on Thursday, April 25, 2013. Until such date, the Company’s common stock will continue to be traded on OTC.BB under its current ticker symbol “MDXG”.
“Listing on the NASDAQ exchange is an integral part of our plan to broaden and strengthen our shareholder base,” said Parker H. “Pete” Petit, MiMedx Chairman and CEO. “We expect the NASDAQ listing will increase the visibility of our stock, provide greater access to our stock and attract a broader range of investors to our stock, each of which is an essential element of our overall strategy to build shareholder value.”
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies are processed from human amniotic membrane that is derived from the donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary Purion® Process, to produce a safe, effective and minimally manipulated implant for homologous use. MiMedx® is the leading supplier of amniotic tissue, having supplied over 140,000 allografts to date to distributors and OEMs for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management’s beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the impact of the NASDAQ listing on the Company’s stock price, shareholder base and shareholder value and the success of the Company’s overall strategy to build shareholder value. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements are that the NASDAQ listing does not have the expected impact on the Company’s stock price, shareholder base and shareholder value, and the risk factors detailed from time to time in the Company’s periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2012. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company’s disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.